VTRS — Viatris Inc.

Summary of Viatris Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $14.3 billion for 2025, representing a 2% increase from 2024 (excluding the impact of divestitures).
• Q4 Revenues: $3.7 billion, up 1% year-over-year (adjusted for divestitures).
• Adjusted EBITDA: $4.2 billion for the year.
• Adjusted EPS: $2.35 per share.
• Free Cash Flow: $2.2 billion (excluding transaction-related costs).
• Capital Return: Over $1 billion returned to shareholders through dividends and share repurchases.

2. Strategic Updates and Business Highlights

• Pipeline Advancements: Five positive phase 3 readouts achieved; full enrollment expected for key trials in 2026.
• Acquisitions: Completed 60 regional transactions, including the acquisition of Aculys Pharma in Japan.
• Cost Optimization: Identified $650 million in gross cost savings over three years, with plans to reinvest $250 million into growth areas.
• Strategic Imperatives: Focus on driving the base business, fueling innovative portfolio growth, and modernizing operations for sustainable growth.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipating approximately 2% growth in total revenues and adjusted EBITDA compared to 2025.
• New Product Contributions: Expected revenues from new products between $450 million and $550 million, with significant launches planned for EFFEXOR and a low-dose estrogen patch.
• Financial Flexibility: Projected robust cash flow generation in 2026, with over $2.5 billion available for deployment.

4. Bad News, Challenges, or Points of Concern

• India Facility Issues: A fire at the Nashik facility has temporarily suspended operations, with a projected restart in April. This incident has been factored into the 2026 guidance.
• Gross Margin Pressures: Anticipated slight declines in gross margins due to product mix shifts and ongoing pricing pressures in certain markets.
• Regulatory Challenges: Facing mandatory price decreases in Japan, impacting revenue and EBITDA, particularly with the anticipated loss of Amitiza mid-year.
• Market Competition: Competitive pressures in the U.S. and Japan, particularly with the loss of exclusivity for certain products.

5. Notable Q&A Insights

• Long-term Growth Path: Management expressed confidence in achieving mid-single-digit revenue growth in the coming years, driven by a stable base business and new product launches.
• Cost Savings Breakdown: Approximately 50% of the $650 million in savings will come from headcount reductions, with the remainder from COGS efficiencies.
• Regulatory Approvals: Six regulatory approvals anticipated in 2026, with management highlighting the importance of these approvals for future growth.
• Launch Strategies: Emphasis on targeted physician engagement for the fast-acting meloxicam, focusing on acute pain management to ensure a successful market entry.

Overall, Viatris Inc. reported solid performance in 2025, with a focus on strategic growth and operational efficiency, while navigating challenges in specific markets and facilities. The outlook for 2026 appears cautiously optimistic, with plans for significant product launches and cost-saving initiatives.